vesemnogene lantuparvovec Clinical Trials
2 recruitingBiologic
Phase 11Phase 21Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 3
Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).
Spinal Muscular Atrophy (SMA)
Lantu Biopharma15 enrolled1 locationNCT07265232
Recruiting
Phase 1Phase 2
An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy
Spinal Muscular Atrophy
Lantu Biopharma20 enrolled1 locationNCT06288230